By Counterforce Health Team in Tavneos (avacopan) —

How to Get Tavneos (Avacopan) Covered by UnitedHealthcare in California: Complete Appeals Guide with Templates

Answer Box: Getting Tavneos Covered by UnitedHealthcare in California

UnitedHealthcare requires prior authorization for Tavneos (avacopan) with strict criteria: severe active ANCA-associated vasculitis (GPA/MPA), use alongside standard therapy (rituximab or cyclophosphamide plus steroids), and specialist prescriber. If denied, California residents can appeal through UnitedHealthcare's internal process, then request an Independent Medical Review (IMR) through the DMHC—which overturns specialty drug denials over 50% of the time.

First step today: Gather your ANCA test results, diagnosis documentation (GPA or MPA), current medication list, and specialist's contact info. Submit the PA request through UnitedHealthcare's provider portal with complete medical records showing combination therapy use.

Table of Contents

  1. Understanding UnitedHealthcare's Tavneos Requirements
  2. Reading Your Denial Letter
  3. Common Denial Reasons & Quick Fixes
  4. Step-by-Step: Fastest Path to Approval
  5. Medical Necessity Letter Checklist
  6. Appeals Process in California
  7. Peer-to-Peer Review Strategy
  8. California Independent Medical Review (IMR)
  9. Cost Support Options
  10. When to File a DMHC Complaint
  11. FAQ

Understanding UnitedHealthcare's Tavneos Requirements

UnitedHealthcare's prior authorization criteria for Tavneos became effective April 1, 2025, and are highly specific. The insurer requires documentation proving you meet all these conditions:

Coverage Requirements Table

Requirement What It Means Documentation Needed Source
Diagnosis Severe active ANCA-associated vasculitis (GPA or MPA) ANCA test results, biopsy reports, specialist notes UHC PA Form
Combination Therapy Must use WITH rituximab OR cyclophosphamide PLUS steroids Current medication list, prescriber attestation UHC PA Form
Specialist Prescriber Rheumatologist, nephrologist, or pulmonologist Provider credentials, NPI number UHC PA Form
Age Requirement 18 years or older Date of birth verification UHC PA Form
Quantity Limits 180 capsules per 30 days Prescription matches approved dosing UHC Provider Portal

Key Point: Tavneos is never approved as monotherapy. UnitedHealthcare explicitly requires ongoing use with standard immunosuppressive agents.

Reading Your Denial Letter

Your UnitedHealthcare denial letter contains critical information for your appeal. Look for these elements:

Essential Information to Extract:

  • Denial reason code (often in fine print)
  • Appeal deadline (typically 180 days for standard appeals)
  • Required forms for appeal submission
  • Fax number or portal for appeals
  • Reference number for tracking
Tip: California law requires denial letters to include specific reasons and your appeal rights. If this information is missing, file a DMHC complaint immediately.

Common Denial Reasons & Quick Fixes

Denial Reason Quick Fix Documents to Submit
"Not prescribed by specialist" Get specialist to submit or co-sign request Specialist credentials, consultation notes
"Missing diagnosis documentation" Submit complete ANCA workup Lab results, biopsy reports, imaging
"Not used with standard therapy" Document current immunosuppressive regimen Current medication list, prescriber attestation
"Quantity limit exceeded" Verify dosing matches FDA labeling Prescription showing 30mg BID (180 caps/month)
"Not medically necessary" Submit comprehensive medical necessity letter Clinical notes, treatment history, outcomes data

Step-by-Step: Fastest Path to Approval

1. Verify Your Diagnosis Documentation

Who does it: Your specialist
Timeline: 1-2 days
Submit via: Medical records to your pharmacy or UnitedHealthcare

Ensure your medical records clearly document:

  • ANCA-positive vasculitis (GPA or MPA)
  • Disease severity markers
  • Organ involvement details

2. Document Current Combination Therapy

Who does it: Prescribing physician
Timeline: Same day
Submit via: UnitedHealthcare provider portal

List all current medications including:

  • Rituximab or cyclophosphamide
  • Corticosteroids (prednisone, etc.)
  • Any other immunosuppressants

3. Submit Prior Authorization Request

Who does it: Healthcare provider
Timeline: 72 hours for standard review
Submit via: UnitedHealthcare provider portal or fax

Include the completed PA form with all supporting documentation.

4. If Denied: Request Peer-to-Peer Review

Who does it: Your specialist
Timeline: 24-48 hours to schedule
Contact: UnitedHealthcare provider services

This allows your doctor to speak directly with UnitedHealthcare's medical director.

5. File Internal Appeal

Who does it: Patient or provider
Timeline: Must file within 180 days of denial
Submit via: UnitedHealthcare appeals department

6. Request California IMR (If Still Denied)

Who does it: Patient
Timeline: Must file within 6 months
Submit via: DMHC website or call 888-466-2219

7. Access Financial Support

Who does it: Patient
Timeline: Ongoing
Contact: Amgen support programs

Medical Necessity Letter Checklist

Your medical necessity letter should address these key points:

Clinical Documentation Required:

  • Patient identification: Name, DOB, member ID
  • Diagnosis: Specific ANCA-associated vasculitis type (GPA/MPA)
  • Disease severity: Birmingham Vasculitis Activity Score (BVAS), organ involvement
  • Prior treatments: Response to previous therapies, adverse effects
  • Current regimen: Specific immunosuppressive agents in use
  • Medical necessity: Why Tavneos is required alongside standard therapy
  • Treatment goals: Expected outcomes, steroid-sparing benefits

Evidence to Include:

  • ANCA test results (MPO or PR3 positive)
  • Tissue biopsy reports (if available)
  • Laboratory values (creatinine, urinalysis, inflammatory markers)
  • Imaging studies showing organ involvement
  • Documentation of steroid-related adverse effects
From our advocates: "We've seen the strongest approvals when specialists explicitly state that Tavneos is being used to reduce steroid burden while maintaining disease control. UnitedHealthcare responds well to clear documentation of steroid toxicity and the need for steroid-sparing agents in combination regimens."

Appeals Process in California

California provides robust appeal rights through both UnitedHealthcare's internal process and state-level review:

Internal Appeals with UnitedHealthcare

Level 1: Standard Internal Appeal

  • Timeline: 30 days for decision
  • How to file: UnitedHealthcare appeals department
  • Required: Denial letter, medical records, physician statement
  • Success rate: Varies, but well-documented cases see higher approval rates

Level 2: Expedited Appeal (if urgent)

  • Timeline: 72 hours for decision
  • Eligibility: Serious threat to health or life
  • How to file: Call UnitedHealthcare member services immediately

External Review Requirements

  • Must complete UnitedHealthcare's internal process first
  • File within 6 months of final internal denial
  • No cost to patient in California

Peer-to-Peer Review Strategy

A peer-to-peer review allows your specialist to speak directly with UnitedHealthcare's medical director. Here's how to maximize success:

Preparation Checklist for Your Doctor:

  • Patient summary: 2-3 sentences on diagnosis and current status
  • Treatment rationale: Why Tavneos is medically necessary
  • Combination therapy: Specific agents being used concurrently
  • Alternative considerations: Why other options aren't suitable
  • Clinical guidelines: Reference to ACR, KDIGO, or other relevant guidance

Key Talking Points:

  1. FDA-approved indication: Tavneos is approved for severe active ANCA-associated vasculitis
  2. Combination requirement: Emphasize use alongside standard therapy, not as replacement
  3. Steroid-sparing benefits: Document steroid-related complications
  4. Disease monitoring: Explain ongoing assessment of disease activity

California Independent Medical Review (IMR)

If UnitedHealthcare upholds their denial after internal appeals, California's IMR process offers a powerful avenue for reversal.

IMR Success Rates

California's DMHC reports that specialty drug appeals have over 50% success rates, with some categories reaching 70% when well-documented.

How to File an IMR:

  1. Complete internal appeals with UnitedHealthcare first
  2. File within 6 months of final denial
  3. Submit via DMHC: Online at dmhc.ca.gov or call 888-466-2219
  4. Include all documentation: Medical records, denial letters, physician statements

What IMR Reviewers Look For:

  • Medical necessity: Clear clinical rationale
  • Guideline support: Alignment with published treatment standards
  • Specialist expertise: Appropriate prescriber involvement
  • Comprehensive documentation: Complete medical picture

IMR Timeline:

  • Standard review: 30 days
  • Expedited review: 7 days (for urgent cases)
  • Decision binding: UnitedHealthcare must comply within 5 business days

Counterforce Health specializes in helping patients navigate complex prior authorization and appeals processes, turning insurance denials into targeted, evidence-backed appeals that align with payer requirements and clinical guidelines.

Cost Support Options

While pursuing coverage, explore these financial assistance programs:

Manufacturer Support (Amgen):

  • Tavneos Co-pay Program: May reduce out-of-pocket costs
  • Patient assistance programs: For uninsured or underinsured patients
  • Contact: Visit tavneos.com for current programs

Foundation Grants:

  • Patient Access Network Foundation: Covers copays for eligible patients
  • HealthWell Foundation: Provides grants for specialty medications
  • Chronic Disease Fund: Supports patients with rare diseases

State Programs:

  • Medi-Cal: California's Medicaid program may cover Tavneos
  • California Prescription Drug Discount Program: Provides reduced pricing

When to File a DMHC Complaint

File a complaint with California's Department of Managed Health Care if:

  • UnitedHealthcare misses appeal deadlines
  • Denial letters lack required information
  • Prior authorization delays exceed reasonable timeframes
  • You experience other procedural violations

How to File:

  • Online: dmhc.ca.gov
  • Phone: 888-466-2219
  • Required information: Member details, timeline, specific violations

The DMHC can investigate and order corrective action, including expedited reviews and coverage decisions.

FAQ

Q: How long does UnitedHealthcare prior authorization take for Tavneos in California? A: Standard review is 72 hours for non-urgent cases. Expedited review for urgent situations is typically completed within 24-72 hours.

Q: What if Tavneos isn't on UnitedHealthcare's formulary? A: You can request a formulary exception with medical necessity documentation. If denied, the California IMR process can review non-formulary denials.

Q: Can I request expedited appeal if my disease is active? A: Yes, if your condition poses a serious threat to your health, you can request expedited review at both the internal appeal and IMR levels.

Q: Does step therapy apply to Tavneos? A: UnitedHealthcare requires combination therapy but doesn't typically require failing other agents first, given Tavneos's unique mechanism and FDA approval.

Q: What happens if I move from another state with prior Tavneos coverage? A: You'll need to restart the prior authorization process with UnitedHealthcare, but prior treatment history strengthens your medical necessity case.

Q: How much does Tavneos cost without insurance? A: Retail pricing is approximately $17,000 per month. Annual costs can reach $170,000-$210,000, making insurance coverage critical.

Q: Can my primary care doctor prescribe Tavneos? A: UnitedHealthcare requires a specialist (rheumatologist, nephrologist, or pulmonologist) to prescribe or co-sign the request.

This guide provides educational information about insurance appeals and is not medical advice. Consult your healthcare provider for medical decisions. For additional help with appeals in California, contact the DMHC Help Center at 888-466-2219 or visit dmhc.ca.gov.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.